The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...

Thermo Fisher Scientific is starting 2026's J.P. Morgan Healthcare Conference with a bang, announcing two new deals with an ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

After a six-month battle, Edwards Lifesciences has been forced to walk away from its nearly $1 billion takeover attempt of ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

Boston Scientific is buying up privately owned medtech Valencia Technologies for its implantable device aimed at helping ...

Eikon Therapeutics is planning to become the second biotech to go public in 2026, in another sign that the public markets are ...

| Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new ...

AbbVie has made no secret of the fact that it’s taken an interest in the hotly contested PD-1xVEGF bispecific space. | AbbVie has made no secret of the fact that it's taken an interest in the hotly ...

In a new letter, Noubar Afeyan, Ph.D., co-founder of Moderna and CEO of Flagship Pioneering, warns that these actions risk undermining the foundations of science itself to the ultimate detriment of ...